Premium
Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010
Author(s) -
Seiji Naito,
Yoshiyuki Kakehi,
Äkïhïko Okuyama,
Tomoaki Imamura,
Hideo Yasunaga,
Hideyuki Akaza,
Shiro Hinotsu,
Yoichi Arai,
Takushi Dokiya,
Shin Egawa,
Kazuhiro Suzuki,
Hirofumi Koga,
Naoya Masumori,
Koichiro Akakura,
Katsuhiro Kawashima,
Koji Okihara,
Kazuto Ito
Publication year - 2010
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2010.02613.x
Subject(s) - medicine , prostate cancer , prostate specific antigen , prostate , prostate cancer screening , cancer , oncology , gynecology
The exposure rate of screening for prostate cancer using prostate‐specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8‐fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.